PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression ; day:29 ; month:1 ; year:2022 ; pages:1-9
Cancer immunology immunotherapy ; (29.1.2022), 1-9
- Creator
-
Filippone, A.
Lanza, M.
Mannino, D.
Raciti, G.
Colarossi, C.
Sciacca, D.
Cuzzocrea, S.
Paterniti, I.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-021-03130-z
- URN
-
urn:nbn:de:101:1-2022050807135482552991
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Filippone, A.
- Lanza, M.
- Mannino, D.
- Raciti, G.
- Colarossi, C.
- Sciacca, D.
- Cuzzocrea, S.
- Paterniti, I.
- SpringerLink (Online service)
Other Objects (12)
Expression von PD1 und PD-L1 in entzündlichen Herzerkrankungen
PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
Expression von PD1 und PD-L1 in entzündlichen Herzerkrankungen
PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
Expression von PD1 und PD-L1 in entzündlichen Herzerkrankungen
PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1